Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 20Carcinoma, Non-Small-Cell Lung 19Pancreatic Neoplasms 17Triple Negative Breast Neoplasms 16Neoplasm Metastasis 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasms 5Lung Neoplasms 4Carcinoma 4Neoplasms by Site 3Adenocarcinoma 3Pancreatic Diseases 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Fallopian Tube Neoplasms 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Pancreatic Ductal 2Carcinoma, Ductal, Breast 2Vaccinia 1Thromboembolism 1Thoracic Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Peritoneal Neoplasms 1Pancreatic cancer, adult 1

Interventions

surufatinib 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pancreatic cancer, adult × 130-nm albumin-bound paclitaxel × Clear all
NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
106 enrolled
Gastrointestinal

Pancreatic cancer, adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡